STOCKHOLM, Jan. 13, 2021 /PRNewswire/ — On Tuesday January 12th, in Mother nature Communications, sturdy preclinical results for a new COVID-19 vaccine, created by the team of Prof. Salanti from University of Copenhagen, ExpreS2ion Biotech, its joint undertaking husband or wife AdaptVac and the Avert-nCoV consortium, was revealed. Primarily based on these success, a scientific trial software (CTA) for a clinical Phase I/II study for the COVID-19 vaccine has been submitted.
About the preclinical outcomes
Readouts from the info display that ABNCoV2 has the probable to be the greatest-in-class COVID-19 vaccine with a far more than 100-fold greater degree of neutralizing antibodies in comparison with posted preclinical animal info from at the moment authorised COVID-19 vaccines, these types of as Pfizer-BioNTech’s, Moderna’s, and AstraZeneca-Oxford’s vaccines. The full paper is offered online and can be examine listed here.
About the CTA
The Medical trial software (CTA) for the ABNCoV2 capsid virus-like particle (cVLP) dependent COVID-19 vaccine was submitted to the Central Committee on Analysis Involving Human Topics (CCMO) in the Netherlands last week. It is expected to be authorised beneath a COVID-19 rapidly-monitor overview development. This can be witnessed as another important milestone subsequent the November 2020 announcement of the successful GMP producing of the vaccine. ExpreS2ion expects to existing preliminary clinical Stage I/IIa effects in advance of finish of Q1 2021.
Due to the fact March 2020, Attana has been assisting the team of Prof. Ali Salanti at the University of Copenhagen in the enhancement of this COVID-19 vaccine with two of Attana’s QCM Biosensors combined with investigate intelligence. As can be witnessed in the paper released, Attana’s technological know-how has foremost been utilised to examine kinetic interactions concerning RBD antigens and CLP-RBD to hACE2. Moreover, Attana and ExpreS2ion recently recognized a strategic partnership like a source agreement of proteins. In addition, Attana technological innovation has been utilised to excellent management the vaccine for the IND submission.
Attana CEO Teodor Aastrup remarks:
“I am thrilled for our companions sake and for the long term of vaccine progress and wish to congratulate all parties involved for obtaining these enjoyable results. I am now hunting forward to discover this collaboration more and to hopefully do the job extra intently with the two Prof. Salanti and the staff at ExpreS2ion in the in the vicinity of time future.”
For additional details, make sure you contact:
+46 () 8 674 57 00
The Board of directors for Attana look at that the info in this push release is not very likely to have a important result on the share selling price but is of normal fascination for the shareholders and that’s why ought to be communicated.
Attana was started in 2002 with the eyesight of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has created proprietary label free biosensors for biochemical, crude, sera, and mobile-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in-vitro diagnostics (IVD) device. Attana products and investigation expert services are utilized by Big Pharma, biotech organizations and educational institutions inside of the everyday living sciences. To discover a lot more about our latest services and goods, remember to visit www.attana.se or contact gross [email protected]
This details was brought to you by Cision https://news.cision.com
The next files are readily available for download:
Watch first written content:https://www.prnewswire.com/information-releases/sizeable-development-built-in-new-covid-19-vaccine-created-by-the-crew-of-prof-salanti-301207197.html